The Double Bay, Australia-based BOD Australia Limited (ASX: BDA) is engaged in the manufacturing and sale of plant-based medicinal cannabis along with health supplements and cosmetic solutions. On March 26th, 2019, the company announced to have completed the experimental aspect of the Phase I Clinical Trial of its sublingual cannabis wafer, guaranteeing its commercial prospects.
The trial was essentially an open-label, randomised, placebo-controlled, four-way crossover study to examine the safety, tolerability, and pharmacokinetics of ECs315 administered as a single or multiple sublingual wafer and oil to around 24 healthy volunteers. The preliminary results obtained highlights the excellence of its proprietary CBD extract ECs315 and patented wafer delivery method, both of which have been termed safe for human consumption showing high tolerability characteristics.
Besides, it was also observed that the CBD from the wafer exhibited faster absorption rates than in oil form and compared to another competitor product. This peculiar feature could be advantageous for patients using cannabis and seeking more rapid relief from their symptoms. The clinical trial report is expected to be finalised in May 2019, and the outcomes will be published in medical journals and research reports thereafter.
With the results in hand, the company is now working on regulatory approvals while developing strategies for commercialisation and export activities, that will further underpin a planned scale up in production. Going forward, the safety data from the trial would be utilised to accelerate market penetration across Europe and the Americas, both possessing significant potential sales upside.
Earlier in March 2019, BOD Australia executed a letter of intent (LOI) with the longstanding partner and Belgian-based natural medicine manufacturer, Tilman S.A, that will distribute BOD’s cannabis range of NutraCabilis and MediCabilis across its current network of pharmacies and specialty retailers in Belgium and Luxemburg. Besides, it also extended its exclusive distribution rights of Tilman’s products in Australia, New Zealand and China (e-commerce) to introduce five new ranges.
The Lambert Initiative also recently placed its first order to BOD for the supply of a pharmaceutical grade GMP produced cannabis extract containing THC and CBD, for its application in a clinical trial relating to Tourette Syndrome.
BOD Australia released its financial results for the half-year ended December 31st, 2018, posting a high improvement of 48.3% in the revenue from ordinary activities to ~ $ 1.08 million as compared to the previous corresponding period (PCP) ended December 31st, 2017. The rise in sales was primarily driven by product suite expansion, new distribution agreements with Priceline and a generally positive product uptake.
There was a simultaneous increase in the loss from ordinary activities after tax attributable to the owners that amounted to ~ $ 2.79 million, up 108% on $ 1.33 million recorded in the PCP. The company remained well capitalised with the net cash and cash equivalents of around $ 6.86 million on account of cash inflows of ~ $ 6.4 million from financing activities.
BOD has a valuation of over AUD 23 million with ~ 69.39 million outstanding shares. At the time of trading on Tuesday, March 26th, 2019, at 03:42 PM AEST, the BDA stock price was trending at AUD 0.360, up 7.46% by AUD 0.025.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.Disclaimer PLEASE BE ADVISED THAT YOUR CONTINUED USE OF THIS SITE OR THE INFORMATION PROVIDED HEREIN SHALL INDICATE YOUR CONSENT AND AGREEMENT TO THESE TERMS. References to ‘Kalkine’, ‘we’, ‘our’ and ‘us’ refer to Kalkine Limited. This website is a service of Kalkine Limited. Kalkine Limited is a private limited company, incorporated in England and Wales with registration number 07903332. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine is not responsible for material posted on this website and does not guarantee the content, accuracy, or use of the content in this site. No advice or information, whether oral or written, obtained by you from Kalkine or through or from the service shall create any warranty not expressly stated. Kalkine do not offer financial advice based upon your personal financial situation or goals, and we shall NOT be held liable for any investment or trading losses you may incur by using the opinions expressed in our publications, market updates, news alerts and corporate profiles. Kalkine does not in any way endorse or recommend individuals, products or services that may be discussed on this site. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a professional licensed financial planner and adviser. Our publications are NOT a solicitation or recommendation to buy, sell or hold.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.